Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | SDHA | P31040 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 11/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839555 | 0.90 | CYP2E1 (0.50) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5838375 | 0.89 | F10 (0.47) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5837649 | 0.88 | MAOB (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5838249 | 0.86 | MAOA (0.58) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5839391 | 0.85 | CYP2E1 (0.49) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5838912 | 0.84 | CYP2E1 (0.50) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5839156 | 0.84 | CYP2E1 (0.50) | CYP2E1MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5217262 | 0.84 | F10 (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5252369 | 0.84 | MAOA (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5215173 | 0.84 | MAOA (0.41) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105547-B2 | Antimicrobial 1-aryl dihydropyridone compounds | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-12 | — | — | US | claimed |
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | GORDEEV MIKHAIL FEDOR (US) | 2005-03-31 | — | — | US | claimed |
| US-7105547-B2 | Antimicrobial 1-aryl dihydropyridone compounds | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | GORDEEV MIKHAIL FEDOR (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | TLR1, QDPR, AP1S1 | CYP2E1 1078/4885MAOA 3032/4885MAOB 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.